Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Robert A. Gerber"'
Autor:
George W. Reed, Robert A. Gerber, Ying Shan, Liza Takiya, Kimberly J. Dandreo, David Gruben, Joel Kremer, Gene Wallenstein
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 573-586 (2019)
Abstract Introduction No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice. Here, we report differences in effectiveness of
Externí odkaz:
https://doaj.org/article/497a18ec2df141b19969821dfab2d550
Autor:
Eric L. Simpson, Gil Yosipovitch, Andrew G. Bushmakin, Joseph C. Cappelleri, Thomas Luger, Sonja Ständer, Wynnis L. Tom, William C. Ports, Michael A. Zielinski, Anna M. Tallman, Huaming Tan, Robert A. Gerber
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 9, Pp 756-761 (2019)
Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship am
Externí odkaz:
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
Autor:
Jonathan I. Silverberg, Anna M. Tallman, William C. Ports, Robert A. Gerber, Huaming Tan, Michael A. Zielinski
Publikováno v:
Acta Dermato-Venereologica, Vol 100, Iss 13, p adv00170 (2020)
Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate atopic dermatitis. This post hoc analysis pools results from 2 phase 3 studies (ClinicalTrials.gov, NCT02118766 [AD-301]; NCT02118792 [AD-
Externí odkaz:
https://doaj.org/article/aaadd477b474454f946fd82746e88b94
Autor:
Evelien Bergrath, Robert A. Gerber, David Gruben, Tatjana Lukic, Charles Makin, Gene Wallenstein
Publikováno v:
International Journal of Rheumatology, Vol 2017 (2017)
Objective. To compare the efficacy and tolerability of tofacitinib, an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA), as monotherapy and combined with disease-modifying antirheumatic drugs (DMARDs) versus biological DMARD
Externí odkaz:
https://doaj.org/article/21c782550cd24a0c8dea63f818a34c3b
Autor:
Amy Cha, Maureen P Neary, Jialu Tarpey, Rachel Hughes, Kyle Fahrbach, Evelien Bergrath Washington, Howard Thom, Joseph C. Cappelleri, Robert A. Gerber
Publikováno v:
Dermatology and Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c9bfc33bdb1eeaef5bbb9d0be487cbab
http://europepmc.org/articles/PMC8611131
http://europepmc.org/articles/PMC8611131
Autor:
Robert A. Gerber, Kimberly J. Dandreo, David Gruben, George W. Reed, Liza Takiya, Ying Shan, Joel M. Kremer, Gene V. Wallenstein
Publikováno v:
Rheumatology and Therapy, Vol 6, Iss 4, Pp 573-586 (2019)
Rheumatology and Therapy
Rheumatology and Therapy
Introduction No published studies exist comparing the effectiveness of tofacitinib with other advanced therapies for the treatment of rheumatoid arthritis (RA) in real-world clinical practice. Here, we report differences in effectiveness of tofacitin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee1643754eb035f2b6e5f56291b6ad26
http://link.springer.com/article/10.1007/s40744-019-00177-4
http://link.springer.com/article/10.1007/s40744-019-00177-4
Autor:
Chao Hsiun Tang, Ping Ning Hsu, Satish Valluri, Der-Yuan Chen, Lindsay Claxton, Robert A. Gerber
Publikováno v:
Journal of Medical Economics. 22:777-787
Aims: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis investigated the cost-effectiveness of the second-line treatment with tofacitinib, ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6b09b3f2f6120ac52f1fc89a6e2899
https://doi.org/10.1080/13696998.2019.1606813
https://doi.org/10.1080/13696998.2019.1606813
Autor:
Wynnis L. Tom, Andrew G. Bushmakin, Eric L. Simpson, Thomas A. Luger, Joseph C. Cappelleri, Anna M. Tallman, Sonja Ständer, Huaming Tan, William C. Ports, Gil Yosipovitch, Michael A. Zielinski, Robert A. Gerber
Publikováno v:
Acta Dermato-Venereologica, Vol 99, Iss 9, Pp 756-761 (2019)
Crisaborole ointment is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis. Using pooled data from two phase 3 studies (NCT02118766/NCT02118792), mediation modeling determined the interrelationship am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d110f2f4fe79d7d66445fed73f24017b
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
https://doaj.org/article/e2d64085c0c24480a5e91c42823e54ba
Autor:
Mohamad Ali Buraik, Joerg Buddenkotte, Haytham Mohamed Ahmed, Khalid Abdullah Mohammad Al-Afif, Anna M. Tallman, Mohamed Mounir, Martin Steinhoff, Robert A. Gerber
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 2, Pp 223-241 (2019)
Dermatology and Therapy
Dermatology and Therapy
Atopic dermatitis (AD) is a common inflammatory skin disease characterized by intensely pruritic lesions. The prevalence of atopic dermatitis is increasing in developing regions, including Africa and the Middle East. However, these regions are underr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21e5d94bae293528f4c4e2aba5b5b427
https://doi.org/10.1007/s13555-019-0285-2
https://doi.org/10.1007/s13555-019-0285-2
Autor:
Eric L. Simpson, Sonja Ständer, Joseph C. Cappelleri, Paul Sanders, Wynnis L. Tom, Andrew G. Bushmakin, Robert A. Gerber, Daniela E. Myers, Gil Yosipovitch, Thomas A. Luger
Publikováno v:
Dermatology and Therapy
Introduction The Investigator’s Static Global Assessment (ISGA) is a 5-point rating scale that is recommended by the US Food and Drug Administration for assessing the severity of atopic dermatitis (AD), and ISGA success is a widely used endpoint in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e22ae870ab754fb322e58fb9d6c522d5
https://pubmed.ncbi.nlm.nih.gov/33751495
https://pubmed.ncbi.nlm.nih.gov/33751495